Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;26(S3):32-37.
doi: 10.1089/dia.2023.0433.

Celebrating the Data from 100,000 Real-World Users of the MiniMed™ 780G System in Europe, Middle East, and Africa Collected Over 3 Years: From Data to Clinical Evidence

Pratik Choudhary  1   2 , Arcelia Arrieta  3 , Tim van den Heuvel  3 , Javier Castañeda  3 , Vittorino Smaniotto  3 , Ohad Cohen  3
Affiliations

Celebrating the Data from 100,000 Real-World Users of the MiniMed™ 780G System in Europe, Middle East, and Africa Collected Over 3 Years: From Data to Clinical Evidence

Pratik Choudhary et al. Diabetes Technol Ther. 2024 Mar.

Abstract

Introduction: The present report celebrates the benchmarking of 100,000 MiniMed™ 780G system users in Europe, Middle East, and Africa (EMEA) and summarizes the major insights into the usability and outcomes of this system. Methods: Carelink Personal data (August 2020-August 2023) of users living in EMEA were analyzed. Continuous glucose monitoring-based endpoints were aggregated for (1) the full cohort and (2) a 12-month longitudinal cohort. Subanalyses were done for users on optimal settings (those spending ≥95% of time with glucose target of 100 mg/dL, and ≥95% of time with active insulin time of 2 h), for self-reported age groups (≤15 and ≥56 years) and for various countries/regions. Results: Data from 101,629 users (34 countries) were analyzed. Mean time in range (TIR) was 72.3%, glucose management indicator (GMI) was 7%, time below 70 mg/dL (TBR70) was 2.0% and time below 54 mg/dL (TBR54) was 0.4%. In terms of international targets, 59.6% of users achieved a GMI <7%, 62.5% a TIR >70%, 88.4% a TBR70 < 4%, and 90.0% a TBR54 < 1%. Data improved impressively in optimal setting users (TIR = 78.8%, and users reaching TIR >70% = 86.3%) while safety remained (TBR70 = 2.2% and TBR54 = 0.4%). Data showed consistency across self-reported age groups and geographies. In the longitudinal cohort, TIR reached 75.5% in the first month and remained 73.3% or higher over the 12-month period. Conclusion: Over 100,000 users of the MiniMed™ 780G system have demonstrated consistency in achieving target control of glycemia.

Keywords: MiniMed™ 780G; Automated insulin delivery; Hybrid closed loop; Real-world evidence.

PubMed Disclaimer

Conflict of interest statement

P.C. has served as speaker for Medtronic events and member of Medtronic advisory boards. Other authors are employees of Medtronic.

Figures

FIG. 1.
FIG. 1.
Glycemic control of real-world MiniMed™ 780G system users. Age groups are based on self-reported age in Carelink Personal. AHCL, advanced hybrid closed loop; GMI, glucose management indicator; SG, sensor glucose.
FIG. 2.
FIG. 2.
Glycemic control of real-world MiniMed™ 780G system users on optimal settings. Age groups are based on self-reported age in Carelink Personal. Optimal settings are defined as a glucose target of 100 mg/dL for at least 95% of the time as well as an active insulin time of 2 h for at least 95% of the time.
FIG. 3.
FIG. 3.
Percentage of real-world MiniMed™ 780G system users that reach international targets. Age groups are based on self-reported age in Carelink Personal. TBR54, time below range (<54 mg/dL); TBR70, time below range (<70 mg/dL); TIR, time in range (70–180 mg/dL).
FIG. 4.
FIG. 4.
Percentage of real-world MiniMed™ 780G system users on optimal settings that reach international targets. Age groups are based on self-reported age in Carelink Personal. Optimal settings are defined as a glucose target of 100 mg/dL for at least 95% of the time as well as an active insulin time of 2 h for at least 95% of the time.
FIG. 5.
FIG. 5.
Glycemic control of real-world MiniMed™ 780G system users over 12 months.
See this image and copyright information in PMC

References

    1. NICE. NICE real-world evidence framework. 2022.
    1. Lewis D. Automated insulin delivery in real life (AID-IRL): Real-world user perspectives on commercial AID. J Diabetes Sci Technol 2022;16(2):500–503. - PMC - PubMed
    1. Jeyaventhan R, Gallen G, Choudhary P, et al. . A real-world study of user characteristics, safety and efficacy of open-source closed-loop systems and Medtronic 670G. Diabetes Obes Metab 2021;23(8):1989–1994. - PubMed
    1. Ioannidis JP, Haidich AB, Pappa M, et al. . Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA 2001;286(7):821–830. - PubMed
    1. ICER. Understanding the Context, Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real World Evidence for Coverage and Formulary Decisions. 2018. - PubMed

LinkOut - more resources